Westlake BioPartners Fund I, L.P. - 31 Dec 2025 SCHEDULE 13G/A Report for Kyverna Therapeutics, Inc. Common Stock, par value $0.00001 per share (KYTX)

Filing Manager
Westlake BioPartners Fund I, L.P.
Reporting Manager
Dr. Beth C. Seidenberg ("Seidenberg")
Security
Kyverna Therapeutics, Inc. Common Stock, par value $0.00001 per share
Symbol
KYTX
Shares outstanding
59,708,423 shares
Disclosed Ownership
4,657,257 shares
Ownership
7.8%
Form type
SCHEDULE 13G/A
Filing time
06 Feb 2026, 15:17:11 UTC
Date of event
31 Dec 2025
SEC
View on sec.gov

Reporting Managers (5)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Westlake BioPartners Fund I, L.P. ("Westlake Fund I") 6.3% 3,787,940 3,787,940 3,787,940 /s/ Jennifer L. Kercher Jennifer L. Kercher/Attorney-in-Fact*, Westlake BioPartners GP I, LLC, Its General Partner
Westlake BioPartners GP I, LLC ("Westlake GP I") 6.3% 3,787,940 3,787,940 3,787,940 /s/ Jennifer L. Kercher Jennifer L. Kercher/Attorney-in-Fact*
Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity Fund I") 1.5% 869,317 869,317 869,317 /s/ Jennifer L. Kercher Jennifer L. Kercher/Attorney-in-Fact*, Westlake BioPartners Opportunity GP I, LLC, Its General Partner
Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I") 1.5% 869,317 869,317 869,317 /s/ Jennifer L. Kercher Jennifer L. Kercher/Attorney-in-Fact*
Dr. Beth C. Seidenberg ("Seidenberg") 7.8% 4,657,257 4,657,257 4,657,257 /s/ Jennifer L. Kercher Jennifer L. Kercher/Attorney-in-Fact*